Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: A single-center experience

Journal of Cardiac Failure

Volumn 20, Issue 4, 2014, Pages 229-235

  Chamsi Pasha, Mohammed A ^a   Dupont, Matthias ^b   Al Jaroudi, Wael A ^c   Tang, W H Wilson ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

acute decompensated heart failure; Mineralocorticoid receptor antagonists; renal insufficiency

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ACUTE HEART FAILURE; ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; UREA NITROGEN BLOOD LEVEL; ACUTE DISEASE; AGED; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84897371413     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.01.017     Document Type: Article

References (17)

1. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
2. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
3. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, and H. Shi et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
4. B.A. Maron, and J.A. Leopold Aldosterone receptor antagonists: effective but often forgotten Circulation 121 2010 934 939
5. N.M. Albert, C.W. Yancy, L. Liang, X. Zhao, A.F. Hernandez, and E.D. Peterson et al. Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665
6. C.W. Yancy, M. Jessup, B. Bozkurt, F.A. Masoudi, J. Butler, and P.E. McBride et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
7. J. Butler, J.A. Ezekowitz, S.P. Collins, M.M. Givertz, J.R. Teerlink, M.N. Walsh Heart Failure Society of America Guidelines Committee Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction J Card Fail 18 2012 265 281
8. J.M. Testani, J. Chen, B.D. McCauley, S.E. Kimmel, and R.P. Shannon Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival Circulation 122 2010 265 272
9. M.J. Krantz, A.V. Ambardekar, L. Kaltenbach, A.F. Hernandez, P.A. Heidenreich, and G.C. Fonarow Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure) Am J Cardiol 107 2011 1818 1823
10. A.F. Hernandez, X. Mi, B.G. Hammill, S.C. Hammill, P.A. Heidenreich, and F.A. Masoudi et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction JAMA 308 2012 2097 2107
11. S. Hamaguchi, S. Kinugawa, M. Tsuchihashi-Makaya, K. Goto, D. Goto, and T. Yokota et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure Am Heart J 160 2010 1156 1162
12. J.P. Ferreira, M. Santos, S. Almeida, I. Marques, P. Bettencourt, and H. Carvalho Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure Eur J Intern Med 25 2014 67 72
13. J.A. Goebel, and A.B. van Bakel Rational use of diuretics in acute decompensated heart failure Curr Heart Fail Rep 5 2008 153 162
14. J.M. Testani, S.E. Kimmel, D.L. Dries, and S.G. Coca Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction Circ Heart Fail 4 2011 685 691
15. O. Vardeny, D.H. Wu, A. Desai, P. Rossignol, F. Zannad, and B. Pitt et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study) J Am Coll Cardiol 60 2012 2082 2089
16. R. Eschalier, J.J. McMurray, K. Swedberg, D.J. van Veldhuisen, H. Krum, and S.J. Pocock et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) J Am Coll Cardiol 62 2013 1585 1593
17. M.S. Jacob, and W.H. Tang Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF Curr Heart Fail Rep 8 2011 7 13